

Pfizer Scandal: CEO Albert Bourla Reveals Two COVID Vaccine Shots Offer ‘Very Limited Protection, If Any’ after Claiming Shot Was ‘100% Effective’

By [Rada Mateescu](#)

Global Research, January 12, 2022

[Health Thoroughfare](#) 11 January 2022

Region: [USA](#)

Theme: [Media Disinformation](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#).

Pfizer is making headlines again after the CEO of the controversial company [Albert Bourla](#) made a recent statement about the efficiency of the [COVID](#) shot.

He recently said in a video that’s all over Twitter that two shots of the covid vaccine offer limited protection against covid 19, “if any.”

Check out the relevant tweet below:

Pfizer CEO: “Two doses of the vaccine offers very limited protection, if any. 3 doses with a booster offer reasonable protection against hospitalization and deaths. Less protection against infection.” [@US_FDA](#) -Come get your boy!

pic.twitter.com/PPRjbyKjY

— Tyler Carditis (@TyCardon) [January 10, 2022](#)

The [controversial video](#) triggered massive backlash considering the fact that back in 2021, the CEO of Pfizer was claiming that the vaccine his company created in 100% effective in preventing covid 19 cases. The has been taken off Twitter, but you can still see it on [this website](#).

Check out his tweet from April 2021:

Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing [#COVID19](#) cases in South Africa. 100%! <https://t.co/E2ksTJSopU>

— Albert Bourla (@AlbertBourla) [April 1, 2021](#)

The internet is filled with a lack of trust these days, after such contracting affirmations.



The image shows a screenshot of a Twitter thread. The main tweet is from Albert Bourla (@AlbertBourla), a verified account, posted on April 1, 2021, at 4:46 PM via the Twitter Web App. The tweet text reads: "Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%! [pfizer.com/news/press-rel...](https://www.pfizer.com/news/press-rel...)". The tweet has 451 retweets, 1,395 quote tweets, and 826 likes. Below the tweet are icons for replying, retweeting, liking, and sharing. A "Tweet your reply" button is visible. The thread continues with two replies from Albert Bourla. The first reply, also from April 1, 2021, says "Replying to @AlbertBourla" and states: "800 participants enrolled in South Africa with 0 cases of #COVID19 observed in the vaccinated group. Of the cases observed the majority were confirmed to be of the B.1.351 lineage, the prevalent strain in South Africa." This reply has 34 replies, 49 retweets, and 77 likes. The second reply, also from April 1, 2021, states: "These data support previous results from immunogenicity studies demonstrating a robust neutralizing antibody response to the B.1.351 variant." This reply has 13 replies, 23 retweets, and 70 likes.

New Omicron Pfizer vaccine will soon be out

Earlier today, we revealed that Pfizer CEO [Albert Bourla](#) on Monday said two doses of the company's vaccine may not provide [strong protection against infection from the Omicron Covid variant](#).

More than that, it's been also revealed that the original shots have also lost some of their efficacy at preventing hospitalization.

He also stated the following:

“The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”

He also made sure to explain the fact that this variant of the virus is a more difficult target than previous variants.

“Omicron, which has dozens of mutations, can evade some of the protection provided by Pfizer’s original two shots.”

FDA and Pfizer controversy

There has been a massive scandal involving the fact that the FDA asked for 75 years to produce Pfizer vaccine safety data. Now, it seems that [things are changing](#), and you should check out the latest reports on the issue below.

It’s been just [reported](#) that the U.S. Food and Drug Administration (FDA) will have eight months — not the 75 years it requested — to release all documents related to the licensing of Pfizer’s Comirnaty [covid](#) vaccine. This is what a federal judge ruled a few days ago.

Also, make sure to check out the [latest scandal](#) involving the virus as we revealed earlier today. And take a look at an extremely interesting interview that [Joe Rogan had with the mRNA inventor, Robert Malone.](#)

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, [@crg_globalresearch](#). Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she’s covering the latest news on these niches.

Featured image is from Health Thoroughfare

The original source of this article is [Health Thoroughfare](#)
Copyright © [Rada Mateescu](#), [Health Thoroughfare](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Rada Mateescu](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants

permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca